EPHA3: Ephrin type-A receptor 3
Receptor tyrosine kinase which binds promiscuously membrane- bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on EPHA3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| KB-004 | Phase 1 | Humanigen, Inc. | Other | InhibitorEphrin type-A receptor 3 inhibitor | 0 |
- Medullary thyroid gland carcinoma0.56
- Neurodegenerative disease0.53
- Atrial fibrillation0.50
- Neoplasm0.44
- Non-small cell lung carcinoma0.43
- Thyroid gland carcinoma0.42
- Alcohol drinking0.39
- Venous thromboembolism0.39
- Pulmonary Infarction0.39
- Pulmonary embolism0.39
- Thyroid tumor0.37
- Intelligence0.36
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4954, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P29320, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets